Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: A retrospective study

Epilepsy Behav. 2019 Sep;98(Pt A):139-144. doi: 10.1016/j.yebeh.2019.07.005. Epub 2019 Jul 30.

Abstract

Cognitive dysfunctions are frequent in patients with epilepsy. This comorbidity significantly alters their quality of life and plays an important role in their therapeutic management. Perampanel is a noncompetitive antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors and is considered a new generation AED (antiepileptic drug) with limited impact on cognitive functions.The aims of this study were to evaluate the efficacy of perampanel as first add-on therapy and its impact on cognitive functions and quality of life in patients with epilepsy followed for 6 months at the Neurology Division of "A. Cardarelli" Hospital in Naples (Italy).

Keywords: Cognitive dysfunction; Perampanel; Quality of life; Seizure.

MeSH terms

  • Adult
  • Anticonvulsants / pharmacology*
  • Cognitive Dysfunction / drug therapy*
  • Cognitive Dysfunction / etiology
  • Drug Therapy, Combination
  • Epilepsy / complications
  • Epilepsy / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitriles
  • Pyridones / pharmacology*
  • Quality of Life*
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Anticonvulsants
  • Nitriles
  • Pyridones
  • perampanel